As well, there were misconceptions that the cost of producing a vaccine would have been lower than at other contract facilities, Plummer says. Moreover, he says none of the four consortiums which pitched cases to build and run the facility could demonstrate that they had a sustainable business model for its long-term operation.
Several experts appeared to bristle at those arguments during testimony before the committee and often directly refuted Plummer's assertions.
Those included Dr. Don Gerson, an international expert in vaccine production and author of the original proposal to develop the facility.
Gerson says there is a serious shortage of facilities that combine the right technology and trained staff needed for small-lot production of vaccines for clinical trials. Too often, smaller contract facilities do not have the controls in place to handle the finicky work of producing such vaccines, but also documenting the production process, he adds.
In some cases, even if such a small facility is up to the task, there can be a commercial conflict of interest if it has already taken on work to produce a trial batch for a competing vaccine, Gerson adds.
"I think there is a lack of knowledge and understanding on the part of the decision-makers," he says. "None has a long history of biopharmaceutical or vaccine manufacturing and thus there is no way for them to really understand the seriousness of the quality requirements."
Gerson also says that those who contend that the facility would have been limited in its production methodologies and just as expensive as other facilities have not carefully studied the proposal.
The CHVI facility would have been able to utilize all three major vaccinemanufacturing methodologies are mistaken, he adds. "If anyone says that it can't be done (at one facility), that is just a statement that they do not know how to do it. I know how, and so do the other people involved in the proposal."
As to cost, Gerson says the price tag for a clinical trial vaccine lot is typically between $500 000 to $1 million. But as a not-for-profit entity, the CHVI facility would have been able to do the same work, under better conditions, for about half that cost, he adds. And because demand for such vaccines is so high, there would have been more than enough work for the facility to be self-sustaining.
Gerson also argues that the global bid to find an HIV vaccine, and other vaccines to treat other afflictions, has been dealt a serious setback. "To be successful in developing an AIDS vaccine, more clinical trials of more vaccines must be conducted. A major limitation is the availability of high quality clinical vaccine lot production. This has been a significant barrier in the past, and remains one even now." -Dan Lett, Winnipeg, Man.
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